Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker

Circulation

Volumn 107, Issue 14, 2003, Pages 1923-1929

  Wang, Chao Hung ^a   Leung, Nathalie ^a   Lapointe, Nathalie ^a   Szeto, Linda ^a   Uffelman, Kristine D ^a   Giacca, Adria ^a,b   Rouleau, Jean L ^a   Lewis, Gary F ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Bradykinin; Diabetes mellitus; Glucose; Hypertension; Insulin

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; DEOXYGLUCOSE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; ICATIBANT; INSULIN; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; OMAPATRILAT; PLACEBO; RAMIPRIL; VASOPEPTIDASE INHIBITOR;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG BINDING; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART MUSCLE; HYPERINSULINISM; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE; STRAIN IDENTIFICATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; BRADYKININ; DRUG SYNERGISM; ENZYME INHIBITORS; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; INSULIN; INSULIN RESISTANCE; LOSARTAN; MALE; MYOCARDIUM; NEPRILYSIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROTEASE INHIBITORS; PYRIDINES; RAMIPRIL; RATS; RATS, ZUCKER; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, BRADYKININ B2; RECEPTORS, ANGIOTENSIN; RECEPTORS, BRADYKININ; THIAZEPINES;

EID: 0037446690     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000062646.09566.CC     Document Type: Article

References (35)

1. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
2. Henriksen EJ, Jacob S, Augustin HJ, et al. Glucose transport activity in insulin-resistant rat muscle: effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes. 1996;45(suppl 1):S125-S128.
3. Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism. 1995;44:267-272.
4. Carvalho CR, Thirone AC, Gontijo JA, et al. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes. 1997;46: 1950-1957.
5. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
6. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
7. Floras JS. Vasopeptidase inhibition: a novel approach to cardiovascular therapy. Can J Cardiol. 2002;18:177-182.
8. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet. 2000; 356:615-620.
9. Nawarskas J, Rajan V, Frishman WH. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Heart Dis. 2001;3:376-385.
10. Coats AJ. Omapatrilat: the story of overture and octave. Int J Cardiol. 2002;86:1-4.
11. Rett K, Wicklmayr M, Dietze GJ, et al. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin, Diabetes. 1996;45(suppl 1):S66-S69.
12. Jaffa AA, Miller DH, Bailey GS, et al. Abnormal regulation of renal kallikrein in experimental diabetes: effects of insulin on prokallikrein synthesis and activation. J Clin Invest. 1987;80:1651-1659.
13. Mayfield RK, Margolius HS, Shimojo N, et al. Renal kallikrein in human and experimental diabetes mellitus. Horm Metab Res Suppl. 1985;15: 31-37.
14. Aguilar-Salinas CA, Arellano SA, Villanueva-Sanchez O. et al. Effects of omapatrilat on blood pressure and insulin sensitivity in an animal model of insulin resistance. Blood Press. 2001;10:164-169.
15. Henriksen EJ, Jacob S, Kinnick TR, et al. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension. 2001;38:884-890.
16. Ishizawa K, Yoshizumi M, Tsuchiya K, et al. Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats. Eur J Pharmacol. 2001;430:359-367.
17. Blais C Jr, Fortin D, Rouleau JL, et al. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther. 2000;295:621-626.
18. Paolisso G, Gambardella A, Saccomanno F, et al. Low-dose iloprost infusion improves insulin action and non-oxidative glucose metabolism in hypertensive patients. Eur J Clin Pharmacol. 1995;48:333-338.
19. DeWitt LM, Putney JW Jr. Stimulation of glycogenolysis in hepatocytes by angiotensin II may involve both calcium release and calcium influx. FEBS Lett. 1983;160:259-263.
20. 2+. Arch Biochem Biophys. 1983;225: 187-195.
21. Kohlman O Jr, Neves FA, Ginoza M, et al. Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension. 1995;25:1003-1007.
22. Motoshima H, Araki E, Nishiyama T, et al. Bradykinin enhances insulin receptor tyrosine kinase in 32D cells reconstituted with bradykinin and insulin signaling pathways. Diabetes Res Clin Pract. 2000;48:155-170.
23. Higaki Y, Hirshman MF, Fujii N, et al. Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes. 2001;50:241-247.
24. Igarashi M, Hirata A, Yamaguchi H, et al. Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. Hypertension. 2001;38:1255-1259.
25. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med. 1996;156:1957-1965.
26. Arbin V, Claperon N, Fournie-Zaluski MC, et al. Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br J Pharmacol. 2001;133:495-502.
27. Colwell DR, Higgins JA, Denyer GS. Incorporation of 2-deoxy-D-glucose into glycogen: implications for measurement of tissue-specific glucose uptake and utilization. Int J Biochem Cell Biol. 1996;28:115-121.
28. Youn JH, Kim JK, Buchanan TA. Time courses of changes in hepatic and skeletal muscle insulin action and GLUT4 protein in skeletal muscle after STZ injection. Diabetes. 1994;43:564-571.
29. Tada H, Thompson CI, Recchia FA, et al. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res. 2000;86:270-274.
30. Recchia FA, Osorio JC, Chandler MP, et al. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am J Physiol. 2002;282:E197-E206.
31. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia. 2000;43:946-952.
32. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229.
33. ω-nitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation. J Nutr. 1996;126: 2563-2567.
34. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
35. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation. 1998;98:2227-2234.